Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciraparantag for Rivaroxaban Reversal
NCT03172910Phase 2Completed
- Start
- May 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ciraparantag (5 arms). Primary endpoints: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) at 1 hour and Subjects Achieving Complete and Sustained Reversal of Anticoagulation (WBCT is ≤115% of Baseline) at 8 hours. Started May 2017; status: completed.
02
Drugs
ciraparantag
Beyond the preview
Go deeper on NCT03172910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172910.